NTAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma

被引：5
|
作者：
Goyal, Lipika [1 ]
Liu, Leah Y. [1 ]
Lennerz, Jochen K. [1 ]
Harding, James J. [2 ]
Huang, Jerry [3 ]
Winkler, Robert [3 ]
Hiroshi, Hirai [4 ]
Ting, David T. [1 ]
Juric, Dejan [1 ]
Corcoran, Ryan B. [1 ]
El-Bardeesy, Nabeel [1 ]
Zhu, Andrew X. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Taiho Oncol Inc, Princeton, NJ USA
[4] Taiho Pharmaceut Co Ltd, Tokyo, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-092
引用
收藏
页数：2
相关论文
共 23 条
  • [1] BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
    Kim, Se Hyun
    Ryu, Haram
    Ock, Chan-Young
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Ji-Won
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Lee, Keun-Wook
    Bang, Soo-Mee
    Kim, Jee Hyun
    Lee, Jong Seok
    Ahn, Joong Bae
    Kim, Kui-Jin
    Rha, Sun Young
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [2] EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma
    Wu, Qibiao
    Zhen, Yuanli
    Shi, Lei
    Vu, Phuong
    Greninger, Patricia
    Adil, Ramzi
    Merritt, Joshua
    Egan, Regina
    Wu, Meng-Ju
    Yin, Xunqin
    Ferrone, Cristina R.
    Deshpande, Vikram
    Baiev, Islam
    Pinto, Christopher J.
    McLoughlin, Daniel E.
    Walmsley, Charlotte S.
    Stone, James R.
    Gordan, John D.
    Zhu, Andrew X.
    Juric, Dejan
    Goyal, Lipika
    Benes, Cyril H.
    Bardeesy, Nabeel
    CANCER DISCOVERY, 2022, 12 (05) : 1378 - 1395
  • [3] BGJ398, a pan-FGFR inhibitor, overcomes paclitaxel resistance in urothelial carcinoma with FGFR1 overexpression
    Ryu, Haram
    Kim, Se Hyun
    Ock, Chan-Young
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Ji-Won
    Kim, Jin Won
    Lee, Jeong-Ok
    Kim, Yu Jung
    Lee, Keun-Wook
    Bang, Soo-Mee
    Kim, Jee Hyun
    Lee, Jong Seok
    Ahn, Joong Bae
    Kim, Kui-Jin
    Rha, Sun Young
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Vu, Phuong
    Deshpande, Vikram
    Kambadakone, Avinash
    Mussolin, Benedetta
    Reyes, Stephanie
    Henderson, Laura
    Sun, Jiaoyuan Elisabeth
    Van Seventer, Emily E.
    Gurski, Joseph M., Jr.
    Baltschukat, Sabrina
    Schacher-Engstler, Barbara
    Barys, Louise
    Stamm, Christelle
    Furet, Pascal
    Ryan, David P.
    Stone, James R.
    Iafrate, A. John
    Getz, Gad
    Porta, Diana Graus
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
  • [5] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Phuong Vu
    Mussolin, Benedetta
    Reyes, Stephanie
    Furet, Pascal
    Iafrate, A. John
    Getz, Gad
    Porta, Diana G.
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER RESEARCH, 2017, 77
  • [6] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
    Javle, Milind M.
    Roychowdhury, Sameek
    Kelley, Robin Kate
    Sadeghi, Saeed
    Macarulla, Teresa
    Waldschmidt, Dirk Thomas
    Goyal, Lipika
    Borbath, Ivan
    El-Khoueiry, Anthony B.
    Yong, Wei-Peng
    Philip, Philip Agop
    Bitzer, Michael
    Tanasanvimon, Suebpong
    Li Ai
    Pande, Amit
    Shepherd, Stacie Peacock
    Moran, Susan
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Javle, M.
    Kelley, R. K.
    Roychowdhury, S.
    Weiss, K. H.
    Abou-Alfa, G. K.
    Macarulla, T.
    Sadeghi, S.
    Waldschmidt, D.
    Zhu, A. X.
    Goyal, L.
    Borad, M.
    Yong, W. P.
    Borbath, I.
    El-Khoueiry, A.
    Philip, P.
    Moran, S.
    Ye, Y.
    Ising, M.
    Lewis, N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
  • [8] TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
    Goyal, Lipika
    Shi, Lei
    Liu, Leah Y.
    de la Cruz, Ferran Fece
    Lennerz, Jochen K.
    Raghavan, Srivatsan
    Leschiner, Ignaty
    Elagina, Liudmila
    Siravegna, Giulia
    Ng, Raymond W. S.
    Phuong Vu
    Patra, Krushna C.
    Saha, Supriya K.
    Uppot, Raul N.
    Arellano, Ron
    Reyes, Stephanie
    Sagara, Takeshi
    Otsuki, Sachie
    Nadres, Brandon
    Shahzade, Heather A.
    DeyGuha, Ipsita
    Fetter, Isobel J.
    Baiev, Islam
    Van Seventer, Emily E.
    Murphy, Janet E.
    Ferrone, Cristina R.
    Tanabe, Kenneth K.
    Deshpande, Vikram
    Harding, James J.
    Yaeger, Rona
    Kelley, Robin K.
    Bardelli, Alberto
    Iafrate, A. John
    Hahn, William C.
    Benes, Cyril H.
    Ting, David T.
    Hirai, Hiroshi
    Getz, Gad
    Juric, Dejan
    Zhu, Andrew X.
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    CANCER DISCOVERY, 2019, 9 (08) : 1064 - 1079
  • [9] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Park, J. O.
    Cassier, P. A.
    Kamath, S. D.
    Meng, D. T. Wai
    Dotan, E.
    Kim, R.
    Sahai, V.
    Oh, D-Y.
    Liao, C-Y.
    Millward, M.
    Perez, D. Roda
    Ferte, C.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1381 - S1381
  • [10] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Park, J. O.
    Meng, D. T. Wai
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Cassier, P.
    Kamath, S. D.
    Dotan, E.
    Kim, R.
    Sahai, V.
    Liao, C-Y.
    Millward, M.
    Roda Perez, D.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1461 - S1462
123